분자종양위원회의 임상적 실제
Clinical Implication of Molecular Tumor Board
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Due to rapid technical advances, steeply declining sequencing costs, and the ever-increasing number of targeted therapies, it is expected that extensive tumor DNA or RNA sequencing will be applied in standard of care. Clinicians will thus be confronted with increasingly complex genetic information and multiple test-platforms to choose from. General medical training, meanwhile, can hardly keep up with the pace of innovation. Consequently, there is a rapidly growing gap between clinical knowledge and genetic potential in cancer care. Multidisciplinary Molecular Tumor Boards (MTBs) have been suggested as a means to address this disparity, as a multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. MTBs are designated to interpret these data and provide clinical recommendations. Not all patients with cancer have access to advice of an MTB. We aimed to determine the current status, opportunities, and challenges of the organization of MTBs in the Korea.
Abstract
Due to rapid technical advances, steeply declining sequencing costs, and the ever-increasing number of targeted therapies, it is expected that extensive tumor DNA or RNA sequencing will be applied in standard of care. Clinicians will thus be confronted with increasingly complex genetic information and multiple test-platforms to choose from. General medical training, meanwhile, can hardly keep up with the pace of innovation. Consequently, there is a rapidly growing gap between clinical knowledge and genetic potential in cancer care. Multidisciplinary Molecular Tumor Boards (MTBs) have been suggested as a means to address this disparity, as a multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. MTBs are designated to interpret these data and provide clinical recommendations. Not all patients with cancer have access to advice of an MTB. We aimed to determine the current status, opportunities, and challenges of the organization of MTBs in the Korea.
참고문헌 (5)
- "Development of genetic information-based precision medical care" (2020)[URL]
- Luchini C, "Molecular tumor boards in clinical practice", Trends Cancer, 6, pp.738~744 (2020)
- Koopman B, "Multicenter comparison of molecular tumor boards in the netherlands : definition, composition, methods, and targeted therapy recommendations", Oncologist, 26, pp.e1347~e1358 (2021)
- Larson KL, "Clinical outcomes of molecular tumor boards : a systematic review", JCO Precis Oncol, 5, pp.1122~1132 (2021)
- 윤신교, "Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group", Cancer Research and Treatment, 54(1), pp.1~9 (2022), 대한암학회[DOI]